Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation

Acta Haematologica

Volumn 131, Issue 2, 2014, Pages 102-111

  Ni, Haiwen ^a   Zhao, Wanzhou ^b   Kong, Xiangtu ^a   Li, Haitao ^c   Ouyang, Jian ^d  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Sino EU Biomedical Innovation Center (SEBIC)   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Angiogenesis; Celastrol; Human multiple myeloma; Nuclear factor kappa B; Toll like receptor 4

Indexed keywords

ANGIOGENIC FACTOR; CELASTROL; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; I KAPPA B ALPHA; TRANSCRIPTION FACTOR RELA;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANTIANGIOGENIC ACTIVITY; CONCENTRATION RESPONSE; DRUG MECHANISM; MULTIPLE MYELOMA CELL LINE; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION; WOUND HEALING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOGENESIS INHIBITORS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; LIPOPOLYSACCHARIDES; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84886023330     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000354770     Document Type: Article

References (66)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet 2009; 374: 324-339
2. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008; 454: 436-444
3. Kyle RA, Rajkumar SV: Multiple myeloma. Blood 2008; 111: 2962-2972
4. Jacobson DR, Zolla-Pazner S: Immunosuppression and infection in multiple myeloma. Semin Oncol 1986; 13: 282-290
5. Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003; 4: 557-564
6. Lauta VM: A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440-2452
7. Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: Short-Term friend, long-Term foe. Clin Cancer Res 2009; 15: 425 430
8. Gupta SC, Kim JH, Prasad S, Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29; 405-434
9. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003; 47: 149-161
10. Cao Y: Tumor angiogenesis and molecular targets for therapy. Front Biosci 2009; 14: 3962-3973
11. Pandya NM, Dhalla NS, Santani DD: Angiogenesis - A new target for future therapy. Vascul Pharmacol 2006; 44: 265-274
12. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395
13. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867
14. Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, Borset M, Espevik T, Sundan A: Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20: 1138-1144
15. Wang XY, Sarkar D, Fisher PB: Stress-sensing Toll-like receptor as a driver of angiogenesis. Pigment Cell Melanoma Res 2011; 24: 7-9
16. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C: Pathogen-Associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20: 1130-1137
17. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859 3868
18. Feinman R, Siegel DS, Berenson J: Regulation of NF-?B in multiple myeloma: Therapeutic implications. Clin Adv Hematol Oncol 2004; 2: 162-166
19. O'Neill LA: How Toll-like receptors signal: What we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9
20. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004; 16: 3-9
21. Kannaiyan R, Shanmugam MK, Sethi G: Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2011; 303: 9-20
22. Yang HS, Kim JY, Lee JH, Lee BW, Park KH, Shim KH, Lee MK, Seo KI: Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and -independent pathways in human breast cancer cells. Food Chem Toxicol 2011; 49: 527-532
23. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, Chaturvedi MM, Aggarwal BB: Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 2010; 88: 1243-1253
24. Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, Lawrence TS, Xu L: Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NFkappaB. PLoS One 2010; 5:e14153
25. Yang H, Chen D,Cui QC , Yuan X, Dou QP: Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine,' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-4765
26. He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W: The NFkappaB inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009; 9: 343
27. Huang Y, Zhou Y, Fan Y, Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008; 264: 101-106
28. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ: Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 2009; 7: 1946-1953
29. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N: Apoptosis induction in HL-60 Cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003; 67: 1883-1887
30. Li Z, Yao L, Li J, Zhang W, Wu X, Liu Y, Lin M, Su W, Li Y, Liang D: Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomed 2012; 7: 1163-1173
31. Huang L, Zhang Z, Zhang S, Ren J, Zhang R, Zeng H, Li Q, Wu G: Inhibitory action of celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1alpha pathway. Int J Mol Med 2011; 27: 407-415
32. Zhou YX, Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: An in vitro and in vivo study. Chin Med J (Engl) 2009; 122: 1666-1673
33. He MF, Liu L, Ge W, Shaw PC, Jiang R, Wu LW, But PP: Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol 2009; 121: 61-68
34. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010; 70: 1951 1959
35. Huang S, Tang Y, Cai X, Peng X, Liu X, Zhang L, Xiang Y, Wang D, Wang X, Pan T: Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2012; 423: 467-472
36. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-2756
37. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M: Acetyl-11-keto-beta-Boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009; 69: 5893-5900
38. Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, Kwon YG: Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004; 64: 644-651
39. Tadema H, Abdulahad WH, Stegeman CA, Kallenberg CG, Heeringa P: Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-Associated vasculitis. PLoS One 2011; 6:e24315
40. Madsen CV, Steffensen KD, Olsen DA, Waldstrom M, Smerdel M, Adimi P, Brandslund I, Jakobsen A: Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J Ovarian Res 2012; 5: 23
41. Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, He Y, Kondo T, Fan J: Decreased seleniumbinding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1alpha to promote hepatocellular carcinoma invasiveness. Clin Cancer Res 2012; 18: 3042 3053
42. Hubackova S, Krejcikova K, Bartek J, Hodny Z: Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem 2012; 287: 26702-26714
43. Tsan MF, Gao B: Endogenous ligands of Tolllike receptors. J Leukoc Biol 2004; 76: 514-519
44. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371
45. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP: Endotoxin/ lipopolysaccharide activates NF-kappaB and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 2003; 170: 795-804
46. Costa C, Incio J, Soares R: Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis 2007; 10: 149-166
47. McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001; 164:S39-S45
48. Rodriguez-Martinez S, Cancino-Diaz ME, Miguel PS, Cancino-Diaz JC: Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via Toll-like receptor 4 in human limbal fibroblasts. Exp Eye Res 2006; 83: 1373-1377
49. Oken MM, Pomeroy C, Weisdorf D, Bennett JM: Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100: 624-628
50. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101: 415-422
51. Oda K, Kitano H: A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol 2006; 2: 2006.0015
52. Yu L, Wang L, Chen S: Endogenous Toll-like receptor ligands and their biological significance. J Cell Mol Med 2010; 14: 2592-2603
53. Wong KF, Yuan Y, Luk JM: Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 2012; 39: 311-320
54. Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B: Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol 2002; 160: 2231-2244
55. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27 42
56. Hara Y, Kuroda N, Inoue K, Sato T: Up-regulation of vascular endothelial growth factor expression by adenosine through adenosine a2 receptors in the rat tongue treated with endotoxin. Arch Oral Biol 2009; 54: 932-942
57. Akira S, Hemmi H: Recognition of pathogenassociated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95
58. Akira S: Mammalian Toll-like receptors. Curr Opin Immunol 200315: 5-11
59. Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto M, Tarakhovsky A: The Toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med 2000; 192: 23-29
60. Sethi G, Tergaonkar V: Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 2009; 30: 313-321
61. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A: Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-Terminal kinase. Blood 2003; 102: 1740-1742
62. Zhou YX, Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: An in vitro and in vivo study. Chin Med J (Engl) 2009; 122: 1666-1673
63. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP, Sethi G: Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-Terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011; 16: 1028-1041
64. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Chng WJ, Sethi G: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-?B and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011; 164: 1506-1521
65. Kim JH, Lee JO, Lee SK, Kim N, You GY, Moon JW, Sha J, Kim SJ, Park SH, Kim HS: Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-Activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cell Signal 2013, 25: 805 813
66. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, Luk JM, Sethi G: Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 2012; 5: 631-643